Acetazolamide (All indications)

Major congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9810
R35101		 Vajda (Acetazolamide) (Controls exposed to Lamotrigine, sick), 2019 Fetal malformations at least 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 18.80 [0.36;971.86] C
excluded (control group) 		0/1   20/406 20 1
ref
S9811
R35102		 Vajda (Acetazolamide) (Controls unexposed, sick), 2019 Fetal malformations at least 1st trimester prospective cohort unexposed, sick Adjustment: No 31.00 [0.56;1711.11] C 0/1   5/176 5 1
ref
S9809
R35099		 Tomson (Acetazolamide), 2018 Malformed Offspring at least 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 32.74 [0.65;1661.58] C 0/1   74/2,514 74 1
ref
S9808
R35097		 Samrén (Acetazolamide), 1999 Major congential abnormalities at least 1st trimester retrospective cohort unexposed, disease free Adjustment: No Matched 69.18 [1.35;3547.68] C 1/1   29/2,000 30 1
ref
Total 3 studies 41.38 [4.21;406.64] 109 3
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Vajda (Acetazolamide) (Controls unexposed, sick), 2019Vajda, 2019 1 31.00[0.56; 1711.11]5132%ROB confusion: criticalROB selection: moderateROB classification: lowROB missing: moderateROB mesure: moderateROB reporting: moderate Tomson (Acetazolamide), 2018Tomson, 2018 2 32.74[0.65; 1661.58]74134%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Samrén (Acetazolamide), 1999Samrén, 1999 3 69.18[1.35; 3547.68]30134%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 41.38[4.21; 406.64]10930.9500.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Acetazolamide) (Controls unexposed, sick; 2: Acetazolamide; 3: Acetazolamide;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 41.38[4.21; 406.64]10930%NAVajda (Acetazolamide) (Controls unexposed, sick), 2019 Tomson (Acetazolamide), 2018 Samrén (Acetazolamide), 1999 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 69.18[1.35; 3547.68]301 -NASamrén (Acetazolamide), 1999 1 unexposed, sickunexposed, sick 31.00[0.56; 1711.11]51 -NAVajda (Acetazolamide) (Controls unexposed, sick), 2019 1 exposed to other treatment, sickexposed to other treatment, sick 32.74[0.65; 1661.58]741 -NATomson (Acetazolamide), 2018 1 Tags Adjustment   - No  - No 41.38[4.21; 406.64]10930%NAVajda (Acetazolamide) (Controls unexposed, sick), 2019 Tomson (Acetazolamide), 2018 Samrén (Acetazolamide), 1999 3 MatchedMatched 69.18[1.35; 3547.68]301 -NASamrén (Acetazolamide), 1999 1 All studiesAll studies 41.38[4.21; 406.64]10930%NAVajda (Acetazolamide) (Controls unexposed, sick), 2019 Tomson (Acetazolamide), 2018 Samrén (Acetazolamide), 1999 30.51000.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9810

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale69.18[1.35; 3547.68]301 -NASamrén (Acetazolamide), 1999 1 unexposed, sick controlsunexposed, sick controls Out of scale31.00[0.56; 1711.11]51 -NAVajda (Acetazolamide) (Controls unexposed, sick), 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale24.85[1.54; 401.75]9420%NAVajda (Acetazolamide) (Controls exposed to Lamotrigine, sick), 2019 Tomson (Acetazolamide), 2018 20.510.01.0